FLT3 and acute myeloid leukemia: Gilteritinib is FDA-approved in relapsed/refractory FLT3-mutated AML based on the ADMIRAL trial, which showed improved median OS vs. salvage chemotherapy (9.3 vs. 5.6 months, p < 0.001) [45].